Cloning — Whole Organism and Gene Cloning

Q1 — Sample Band 6 response (8 marks), annotated

Effectiveness, in a biotechnology context, refers to how well a process achieves its intended purpose — judged against success rate, fitness-for-purpose and limitations, not merely whether copying occurred. [1 — definition]

Whole-organism cloning by somatic-cell nuclear transfer (SCNT) has a strikingly low success rate. The Dolly experiment produced just 1 live lamb from 277 reconstructed embryos — an overall success rate of ≈0.36% — and over 90% of established pregnancies miscarried before birth. [1 — two quantitative values used] Across species, the stimulus graph shows that even the best-performing mammals (cow ≈2.0%, dog ≈1.8%) yield only one live birth per ~50 attempts, while sheep — Dolly's species — sit at ≈0.4% and rhesus macaques at ≈0.6%. No species has reached even 5% efficiency, almost three decades after Dolly. [1 — uses inter-species comparison]

Two biological mechanisms explain these low rates. First, the donor somatic nucleus must be reprogrammed by the egg cytoplasm to drive embryonic development, and incomplete reprogramming causes early embryonic arrest — accounting for the loss of about 89% of embryos before implantation in the Dolly data. [1 — limitation 1: reprogramming] Second, even when pregnancy is established, abnormal placental development ("large offspring syndrome") and inappropriate gene expression from the somatic nucleus cause the high miscarriage rate, and surviving clones (including Dolly, who developed severe osteoarthritis at age 5) can show developmental and ageing abnormalities — the lesson's "phenotype is not guaranteed" warning in action. [1 — limitation 2: placental/phenotype]

Despite these limitations, SCNT is fit-for-purpose for narrow applications: preserving an elite livestock genotype (cattle with high milk yield), producing transgenic founder animals that secrete therapeutic proteins in their milk (e.g. PPL Therapeutics' antithrombin-producing sheep), and — in principle — preserving genetic material from highly endangered species. In these contexts, a 1–2% success rate is acceptable because each live clone has high commercial or conservation value. [1 — legitimate application acknowledged]

Overall, whole-organism cloning is biologically significant but practically limited: it is not a routine, high-yield way to copy mammals, but it is effective for specific high-value, low-volume purposes. The honest evaluation is purpose-dependent — the technology is effective for what it can realistically deliver, and ineffective if used as a general-purpose mammal-replication service. [1 — judgement: purpose-dependent, no one-winner ranking] Stronger Band 6 answers will also note that the data are dominated by mammals — invertebrate and amphibian SCNT (e.g. Xenopus) shows much higher efficiencies, reinforcing that "effectiveness of cloning" is not a single number. [1 — overall coherence / sophistication]

Marking criteria.

• 1 mark — Defines effectiveness as goal-relative (success rate + fitness-for-purpose + limitations).
• 1 mark — Cites at least one Dolly-specific statistic (277 → 1; ≈0.36%; or pregnancy loss > 90%).
• 1 mark — Cites at least one inter-species statistic from the graph (e.g. cow ≈2.0%, sheep ≈0.4%).
• 1 mark — Identifies nuclear reprogramming failure or pre-implantation embryo loss as a limitation.
• 1 mark — Identifies placental abnormality / "large offspring syndrome" / phenotype-not-guaranteed as a separate limitation.
• 1 mark — Identifies a legitimate, named application where SCNT is fit-for-purpose despite low efficiency.
• 1 mark — Reaches an explicit purpose-dependent judgement (effective for narrow goals, not as a general technology) rather than a blanket verdict.
• 1 mark — Uses precise lesson terminology throughout (SCNT, enucleated egg, somatic, surrogate, effectiveness) and integrates the data into the argument rather than listing it.

Q2 — Sample Band 6 response (8 marks), annotated

In gene cloning a chosen DNA sequence is inserted into a vector and replicated in a host cell. In the Humulin process, the human INS gene is the target sequence, the vector is a bacterial plasmid (a derivative of pBR322), and the host cell is E. coli, which divides repeatedly in industrial fermenters to produce many copies of the gene and express it as human insulin protein. [1 — process with vector and host correctly named]

The data show that gene cloning has been spectacularly effective for this purpose. Annual global insulin production rose from ≈2 tonnes (animal extraction, 1980) to ≈40 tonnes (recombinant, 2020) — a roughly 20-fold increase — and the number of patients supplied climbed from ~10 million to ~200 million. [1 — uses 2 quantitative values from stimulus]

The two methods can be compared on at least four criteria. Yield: producing 1 kg of insulin once required ≈8 000 kg of pancreas tissue from ~25 000 pigs; now it requires ~1 000 L of bacterial culture, an enormous gain in efficiency. Scalability: bacterial fermenters can be scaled by adding fermenters, while pig-pancreas supply is bounded by livestock numbers and slaughter throughput. Product fidelity: pig insulin differs from human insulin at one amino acid and cow at three, causing immune reactions in some patients; recombinant Humulin matches the human sequence exactly. Safety: animal pancreas extraction carries a contamination risk (other animal proteins, pathogens) that bacterial fermentation under controlled conditions minimises. [1 — three or more comparison criteria; 1 — links comparison to product fidelity / patient safety]

Gene cloning is not without limitations. Bacterial hosts cannot perform mammalian post-translational modifications, so insulin (a relatively simple peptide) is suitable but more complex proteins may require yeast or mammalian-cell expression systems. Endotoxins from E. coli must be rigorously removed before the product is clinical-grade, and the patents and regulatory pathway concentrate production in a small number of multinational companies — affecting price and access in many countries. [1 — acknowledges at least one honest limitation]

Comparing this case to whole-organism cloning (Q1), the contrast in effectiveness is sharp. Whole-organism cloning achieves ≈0.4–2% live-birth efficiency and cannot guarantee identical phenotype; the same technology framework — gene cloning — achieves industrial-scale, identity-faithful production of a life-saving human protein on a global timescale. The reason for this difference is exactly what the lesson predicts: gene cloning's goal is narrow and well-defined (copy one DNA sequence; express one protein), while whole-organism cloning's goal is to produce a viable developing organism — a far harder problem. [1 — explicit cross-link to Q1 with mechanism]

Therefore, evaluated by the lesson's "fit-for-purpose" criterion, gene cloning is highly effective for the Humulin task — it has saved millions of lives, scaled cleanly, and outperformed the prior technology on every measurable criterion. The honest evaluation is still purpose-dependent: gene cloning is not always the right tool (e.g. when post-translational modifications matter, or when a whole organism is genuinely the goal), but for producing a defined protein at scale it is one of the clearest biotechnology success stories. [1 — explicit overall judgement linked to "assess by goal"; 1 — coherent precise terminology]

Marking criteria.

• 1 mark — Outlines gene cloning correctly (target gene → vector → host → replication / expression) with vector named (bacterial plasmid) and host named (E. coli).
• 1 mark — Cites at least two quantitative values from the stimulus (e.g. 2 t → 40 t per year; 10 M → 200 M patients; 8 000 kg → 1 000 L feedstock; 1982 launch).
• 1 mark — Compares gene cloning vs animal extraction on at least three criteria (yield, scalability, fidelity, safety).
• 1 mark — Explicitly addresses product fidelity and/or patient-safety advantages of the recombinant approach.
• 1 mark — Acknowledges at least one honest limitation of gene cloning (post-translational modification limits, endotoxin removal, regulatory/patent concentration, host cell biology).
• 1 mark — Cross-links to Q1 (whole-organism cloning) and explains the gene-cloning vs whole-organism cloning effectiveness gap using the narrow-vs-broad goal distinction from Card 1.
• 1 mark — Reaches an explicit, purpose-dependent overall judgement using lesson terminology (effectiveness, vector, host cell, fit-for-purpose).
• 1 mark — Integrates the data into the argument (not listed in isolation) and uses sustained Band 6 register.